Navigation Links
KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody
Date:12/10/2013

evention and treatment of Pseudomonas aeruginosa (Pa) infection. KaloBios has retained rights for the cystic fibrosis indication and is conducting a 180 patient Phase 2 study in CF subjects with chronic Pa lung infection in the United States.  KaloBios has received Orphan Drug designation from both the U.S. FDA and the European Medicines Agency for KB001-A for the treatment of Pa lung infection in CF patients. Sanofi is pursuing a ventilator-associated pneumonia prevention indication in the intensive care setting, an indication which has received U.S. FDA Fast Track Designation.
  • KB004, an anti-EphA3 mAb, has potential in treating hematologic malignancies and solid tumors. KaloBios is currently testing this drug in a Phase 1 study in subjects with hematologic malignancies.
  • All of the company's antibodies were generated using its proprietary Humaneered® technology, a method that converts nonhuman antibodies (typically mouse) into recombinant antibodies that have a high binding affinity to their target and are designed for chronic therapeutic use. The company believes that antibodies produced using its Humaneered® technology offer important clinical and economic advantages over antibodies generated by other methods in terms of high binding affinity, high manufacturing yields, and minimal to no immunogenicity (inappropriate immune response) upon repeat administration in humans.

    For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.

    Forward Looking Statements
    This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: the statements under the heading "Anticipated Upcoming Milestones"; and statements regarding the company's clinical
    '/>"/>

    SOURCE KaloBios Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology news :

    1. KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
    2. Wyss Institute at Harvard University announces election of 2 faculty to Natl Academy of Inventors
    3. Reproductive Health Matters announces publication of its latest themed issue: New development paradigm
    4. Afterburn Fuel Review Announces the Launch of its New and Informative Website
    5. VaxTrac Announces Continued Support for Expansion of Biometric-based Mobile Vaccine Registry Programs in Benin
    6. AIBS announces winners of Faces of Biology photo competition
    7. NERC announces the winner of its first photo and essay competition
    8. Elsevier announces the launch of open access journal: Current Plant Biology
    9. AVS Announces Its Major Award Winners of 2013
    10. The Association for Molecular Pathology announces highlights of Phoenix meeting
    11. EMBO announces the launch of EMBO Press
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
    (Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
    (Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
    Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
    ... COLLEGE PARK, Md. - The first Maryland municipality to ... environmental program is the Town of Berlin on the ... - managed by the University of Maryland,s Environmental Finance ... their assets, as well as revitalize and improve their ...
    ... available in German . , In a variant ... kernels on the cob are not ,naked, but covered by long ... Planck Institute for Plant Breeding Research in Cologne and Friedrich Schiller ... leaf gene in the maize cob that is not usually active ...
    ... in cocoa has been developed by a team of ... Incorporated, and recently published in the Journal of ... in flavanol chemistry and analytics, the method identifies and ... cocoa and chocolate products. Foods rich in flavanols are ...
    Cached Biology News:Maryland gets its first 'Certified Sustainable' community: Berlin 2Pod corn develops leaves in the inflorescences 2Pod corn develops leaves in the inflorescences 3Scientists advance field of research with publication of newly validated method for analyzing flavanols in cocoa 2
    (Date:5/22/2015)... Warren, NJ (PRWEB) May 22, 2015 ... a new white paper that explores the potential of ... industries. The white paper was developed to help life ... they can leverage data to gain critical business insights. ... generated large amounts of data driven by patient profiling, ...
    (Date:5/21/2015)... 21, 2015  Susan Hedstrom, Executive Director of ... organization dedicated to supporting research to advance the ... today that FPWR has received the organization,s largest ... contributed $1 million in support of the ... "Our gift signifies our ...
    (Date:5/21/2015)... Germany (PRWEB) May 21, 2015 ... that its manufacturing facility in Worms, Germany has ... an independent subsidiary of the International Pharmaceutical Excipient ... Grace facilities that produce its SYLOID® FP brand ... received GMP certification, following the Curtis Bay, Maryland ...
    (Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company focused on the ... upcoming poster presentation at the International Society for ... for chronic Achilles tendinosis currently in a Phase ... May 29 th from 5:30 PM to ...
    Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
    ... KANSAS CITY, Mo., Feb. 24 An investor group ... Irish based developer and manufacturer of,diagnostic products, has petitioned ... compliance with key company law provisions designed,to permit communication ... The petition as filed asserts that Irish-based independent ...
    ... region,certainly has not been immune to our country,s economic ... has seen their highest,demand for services in over 10 ... & wellness event, the Charlotte Anti-Aging Expo &,Symposium, wants ... "We can all have a vibrant and healthy ...
    ... - Syndicate Comprises Leading ... Novartis Option Fund , ... on drugs,targeting G-protein-coupled receptors (GPCRs), announces today it ... in a successful Series A,private round from three ...
    Cached Biology Technology:Charlotte Anti-Aging Expo & Symposium Supports Free Clinics 2Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets 2Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets 3Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets 4Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets 5
    ...
    Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
    Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
    Mouse monoclonal antibody raised against a partial recombinant EOMES. NCBI Entrez Gene ID = EOMES...
    Biology Products: